Tuesday 30 Apr 2024
By
main news image

KUALA LUMPUR (May 10): CGS-CIMB Research has maintained its “hold” rating on Karex Bhd at 38.5 sen with an unchanged target price of 40 sen. It said the condom maker should see a recovery in condom sales in its fourth financial quarter ending June 30, 2022 (4QFY22), thanks to the lifting of lockdown restrictions globally as well as new customer acquisitions.

In a note on Monday (May 9), the research house said it expects weaker quarter-on-quarter earnings in 3QFY22 due to production disruptions, with higher selling prices and increase in condom sales from 4QFY22.

CGS-CIMB Research said Karex is still seeing production disruptions leading to lower output (utilisation rate in 3QFY22F was estimated at 55-60% versus 65-70% pre-Covid-19 pandemic).

It said this is a result of issues such as positive Covid-19 cases among employees, freight delays for shipment of raw material and labour shortages.

“However, Karex is confident of raising its production output from 4QFY22 onwards, backed by fewer Covid-19 restrictions such as no social distancing or mandatory quarantine for close contacts," it added.

      Print
      Text Size
      Share